Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Kilitch Drugs (India) Ltd. Share Price
Day's Range
Day's Range
Low
₹153.64
High
₹159.50
Price Summary
| Previous Close | ₹157.68 |
|---|---|
| Day's Range | ₹153.64 - ₹159.50 |
| Open | ₹155.00 |
| 52 Week Range | ₹117.25 - ₹250.00 |
| Volume | 40,215 |
| Market Cap | ₹0.00 |
| Previous Close | ₹156.20 |
|---|---|
| Day's Range | ₹153.55 - ₹159.00 |
| Open | ₹154.70 |
| 52 Week Range | ₹121.10 - ₹245.00 |
| Volume | 3,248 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 63.41 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 20.78 |
| TTM EPS (₹) | 7.45 |
| P/E Ratio | 21.31 |
| Book Value(₹) | 1.88 |
| PAT Margin (%) | 12.58 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 17.31 |
| Trade Value ( ₹ in Lacs) | 5.07 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 20.78 |
| TTM EPS (₹) | 7.45 |
| P/E Ratio | 21.31 |
| Book Value(₹) | 1.88 |
| PAT Margin (%) | 12.58 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 17.31 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 561.66 | 1315.99 |
| Expenses | N/A | N/A |
| PBT | 82.51 | 233.54 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 56.15 | 175.74 |
About Kilitch Drugs (India) Ltd.
| Founded | 1992 |
|---|---|
| Managing Director | Mukund P Mehta |
| NSE Symbol | KILITCH |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,43,972.94 | 1,831.30 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,025.88 | 6,681.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,477.60 | 4,351.60 | 3,101.60 - 3,101.60 |
| Lupin Ltd. | 1,11,668.12 | 2,460.50 | 1,836.80 - 1,836.80 |
| Apollo Hospitals Enterprise Ltd. | 1,11,526.57 | 7,820.45 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,10,282.52 | 1,361.00 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,381.80 | 1,307.00 | 1,138.50 - 1,138.50 |
| Max Healthcare Institute Ltd. | 98,852.37 | 1,015.10 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,505.92 | 2,375.40 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,495.43 | 940.10 | 835.50 - 835.50 |
No Records Found
Latest News
Kilitch Drugs India informs about board meeting
Kilitch Drugs (India) informs about closure of trading windows
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with Code of Prohibition of Insider Trading of the Company, Kilitch Drugs (India) has informed that the Trading Windows for dealing in Securities of the Company will remain closed for all the Designated Persons of the Company and their immediate relatives with effect from Wednesday, 1st April, 2026 till the expiry of 48 hours after the declaration of Financial Results of the Company for the quarter and year ended 31st March, 2026. The date of meeting of Board of Directors to approve the audited financial results of the Company for the quarter and year ended 31st March, 2026 shall be intimated in due course
The above information is a part of company’s filings submitted to BSE.
Kilitch Drugs (India) informs about record date
Pursuant to the Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and on receipt of approval of shareholders, Kilitch Drugs (India) has informed that the Company has fixed Tuesday, 24th March, 2026 as the Record Date in order to determine the number of shareholders entitled for Bonus Equity shares in the ratio of 1:1 (i.e. One bonus equity share of Rs. 10/- each for every one equity share of Rs. 10/- each held by the shareholders). Further, in accordance with SEBI circular dated 16th September, 2024, the deemed date of allotment of Bonus Equity Shares shall be Wednesday, 25th March, 2026. The shareholders whose names stand registered on the Company’s register of Members in respect of physical shares and on the Register of beneficial owners maintained by Depositories in respect of the shares held in electronic form as of closing hours of Tuesday, 24th March, 2026 shall be entitled to receive the bonus equity shares.
The above information is a part of company’s filings submitted to BSE.
Global Longlife Hospital and Research informs about outcome of board meeting
Panacea Biotec informs about updates
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Kilitch Drugs (India) Ltd. is ₹157.68 as of 2026-05-07.
The market capitalisation of Kilitch Drugs (India) Ltd. is ₹541.38 as of 2026-05-06.
The 1-year return of Kilitch Drugs (India) Ltd. is 0.00% as of 2026-05-07.
The P/E ratio of Kilitch Drugs (India) Ltd. is 21.31 as of 2026-05-07.
The 52-week high and low of Kilitch Drugs (India) Ltd. are ₹250.00 and ₹117.25, respectively, as of 2026-05-07.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
